EE03484B1 - Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine - Google Patents

Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine

Info

Publication number: EE03484B1
Authority: EE; Estonia
Prior art keywords: imidazolyl; methyl; protein transferase; farnesyl protein; quinolinone derivatives
Prior art date: 1995-12-08

Application number

EE9800146A

Other languages

English (en)

Estonian (et)

Other versions

EE9800146A (et

Inventor

Gaston Venet Marc

Ren� Angibaud Patrick

Charles Sanz G�rard

Muller Philippe

Original Assignee

Janssen Pharmaceutica N.V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-08

Filing date

1996-10-16

Publication date

2001-08-15

1996-10-16 Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.

1998-10-15 Publication of EE9800146A publication Critical patent/EE9800146A/xx

2001-08-15 Publication of EE03484B1 publication Critical patent/EE03484B1/xx

Links

AVGQUILLCRPWKH-UHFFFAOYSA-N 4-(1h-imidazol-5-yl)-3-methyl-1h-quinolin-2-one Chemical class C12=CC=CC=C2NC(=O)C(C)=C1C1=CN=CN1 AVGQUILLCRPWKH-UHFFFAOYSA-N 0.000 title 1
102000004357 Transferases Human genes 0.000 title 1
108090000992 Transferases Proteins 0.000 title 1
125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

EE9800146A 1995-12-08 1996-10-16 Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine EE03484B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP95203427		1995-12-08
PCT/EP1996/004515 WO1997021701A1 (fr)	1995-12-08	1996-10-16	Derives de la (imidazol-5-yl)methyl-2-quinoleinone comme inhibiteur de la proteine farnesyle-transferase

Publications (2)

Publication Number	Publication Date
EE9800146A EE9800146A (et)	1998-10-15
EE03484B1 true EE03484B1 (et)	2001-08-15

Family

ID=8220926

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EE9800146A EE03484B1 (et)	1995-12-08	1996-10-16	Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine

Country Status (36)

Country	Link
US (3)	US6037350A (fr)
EP (2)	EP1162201B1 (fr)
JP (1)	JP3257559B2 (fr)
KR (1)	KR100272676B1 (fr)
CN (1)	CN1101392C (fr)
AP (1)	AP1108A (fr)
AR (1)	AR004992A1 (fr)
AT (2)	ATE321757T1 (fr)
AU (1)	AU711142B2 (fr)
BG (1)	BG62615B1 (fr)
BR (1)	BR9610745A (fr)
CA (1)	CA2231105C (fr)
CY (1)	CY2289B1 (fr)
CZ (1)	CZ293296B6 (fr)
DE (2)	DE69620445T2 (fr)
DK (2)	DK1162201T3 (fr)
EA (1)	EA000710B1 (fr)
EE (1)	EE03484B1 (fr)
ES (2)	ES2175137T3 (fr)
HK (1)	HK1042482B (fr)
HR (1)	HRP960576B1 (fr)
HU (1)	HU221227B1 (fr)
IL (1)	IL123568A (fr)
MX (1)	MX9802068A (fr)
MY (1)	MY114444A (fr)
NO (1)	NO314036B1 (fr)
NZ (1)	NZ320244A (fr)
PL (1)	PL184171B1 (fr)
PT (2)	PT1162201E (fr)
SI (2)	SI0865440T1 (fr)
SK (1)	SK283335B6 (fr)
TR (1)	TR199800825T2 (fr)
TW (1)	TW494101B (fr)
UA (1)	UA57717C2 (fr)
WO (1)	WO1997021701A1 (fr)
ZA (1)	ZA9610254B (fr)

Families Citing this family (239)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2175137T3 (es) *	1995-12-08	2002-11-16	Janssen Pharmaceutica Nv	Derivados de (imidazol-5-il)metil-2-quinolinona como inhibidores de laproteina farnesil-transferasa.
TR199902923T2 (xx) *	1997-06-02	2000-11-21	Janssen Pharmaceutica N.V.	Yumu�ak kas h�cresi �o�almas� inhibit�rleri olarak (imidazol-5-il)metil-2-kuinolinon t�revleri.
US20030114503A1 (en) *	1997-06-16	2003-06-19	Pfizer Inc.	Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
US6420555B1 (en) *	1998-06-16	2002-07-16	Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S.	Imidazolyl derivatives
AU4822299A (en) *	1998-06-16	2000-01-05	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)	Imidazolyl derivatives
WO2000001411A1 (fr) *	1998-07-06	2000-01-13	Janssen Pharmaceutica N.V.	Inhibiteurs de farnesyl proteine transferase a proprietes de radiosensibilisation in vivo
HRP20000904A2 (en) *	1998-07-06	2001-12-31	Janssen Pharmaceutica Nv	Farnesyl protein transferase inhibitors for treating arthropathies
FR2780892B1 (fr) *	1998-07-08	2001-08-17	Sod Conseils Rech Applic	Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
EA200100135A1 (ru) *	1998-08-27	2001-08-27	Пфайзер Продактс Инк.	Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов
BR9913315A (pt)	1998-08-27	2001-05-22	Pfizer Prod Inc	Derivados de quinolin-2-ona úteis como agentes anticâncer
WO2000034437A2 (fr)	1998-12-08	2000-06-15	Merck & Co., Inc.	Inhibiteurs de prenyl-proteine transferase
WO2000034239A2 (fr)	1998-12-08	2000-06-15	Merck & Co., Inc.	Inhibiteurs de prenyl-proteine transferase
TR200101961T2 (tr) *	1998-12-23	2001-12-21	Janssen Pharmaceutica N.V.	1,2-halkalı kinolin türevleri
UA71945C2 (en)	1999-01-27	2005-01-17	Pfizer Prod Inc	Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja)	1999-01-27	2002-04-02	ファイザー・プロダクツ・インク	抗がん剤として有用なヘテロ芳香族二環式誘導体
KR20010102073A (ko) *	1999-02-11	2001-11-15	실버스타인 아써 에이.	항암제로 유용한 헤테로아릴-치환된 퀴놀린-2-온 유도체
US6143766A (en) *	1999-04-16	2000-11-07	Warner-Lambert Company	Benzopyranone and quinolone inhibitors of ras farnesyl transferase
EP1420015A1 (fr) *	1999-06-11	2004-05-19	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Dérivés de l'imidazole
FR2796943A1 (fr) *	1999-07-30	2001-02-02	Aventis Pharma Sa	Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
RU2298417C2 (ru) *	1999-11-09	2007-05-10	Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик (С.К.Р.А.С.)	Продукт, включающий ингибитор трансдукции сигналов гетеротримерных протеинов g в комбинации с другим цитостатическим средством, для терапевтического применения при лечении рака
TR200400342T4 (tr) *	1999-11-30	2004-03-22	Pfizer Products Inc.	Farnezil protein transferazı önlemek için kinolin türevleri.
HN2000000266A (es) *	2000-01-21	2001-05-21	Pfizer Prod Inc	Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
CA2396865C (fr) *	2000-02-04	2009-04-14	Janssen Pharmaceutica N.V.	Inhibiteurs de la farnesyl proteine transferase pour le traitement du cancer du sein
DE60130976T2 (de) *	2000-02-24	2008-07-17	Janssen Pharmaceutica N.V.	Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
US20030022918A1 (en) *	2000-02-29	2003-01-30	Horak Ivan David	Farnesyl protein transferase inhibitor combinations with an her2 antibody
AU2001240658A1 (en) *	2000-02-29	2001-09-12	Janssen Pharmaceutica N.V.	Farnesyl protein transferase inhibitor combinations with camptothecin compounds
JP2003525236A (ja) *	2000-02-29	2003-08-26	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ビンカアルカロイドとのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
CA2397694A1 (fr) *	2000-02-29	2001-09-07	Janssen Pharmaceutica Inc.	Combinaisons d'inhibiteur de farnesyl-proteine transferase
EP1261348A2 (fr) *	2000-02-29	2002-12-04	Janssen Pharmaceutica N.V.	Combinaisons d'inhibiteur de farnesyl proteine transferase et d'agents d'alkylation antitumoraux
AU2001244166A1 (en) *	2000-02-29	2001-09-12	Janssen Pharmaceutica N.V.	Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
EP1261356A2 (fr) *	2000-02-29	2002-12-04	Janssen Pharmaceutica N.V.	Combinaisons d'inhibiteur de farnesyl proteine transferase et de composes de platine
WO2001064197A2 (fr) *	2000-02-29	2001-09-07	Janssen Pharmaceutica N.V.	Combinaisons d'inhibiteurs de farnesyl proteine transferase et de derives antitumoraux d'anthracycline
US20030181473A1 (en) *	2000-02-29	2003-09-25	Palmer Peter Albert	Farnesyl protein transferase inhibitor combinations with taxane compounds
CA2397690A1 (fr) *	2000-02-29	2001-09-07	Janssen Pharmaceutica N.V.	Inhibiteur de farnesyl proteine transferase associe a des derives nucleosidiques anti-cancereux
AU2001239275A1 (en) *	2000-02-29	2001-09-12	Janssen Pharmaceutica N.V.	Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
US6844357B2 (en) *	2000-05-01	2005-01-18	Pfizer Inc.	Substituted quinolin-2-one derivatives useful as antiproliferative agents
JO2361B1 (en)	2000-06-22	2006-12-12	جانسين فارماسيوتيكا ان. في	Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
AU2001293829A1 (en) *	2000-09-25	2002-04-02	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 6-((substituted phenyl)methyl)-quinoline and quinazoline derivatives
ATE321038T1 (de)	2000-09-25	2006-04-15	Janssen Pharmaceutica Nv	Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
AU2001293835A1 (en) *	2000-09-25	2002-04-02	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
WO2002024686A2 (fr)	2000-09-25	2002-03-28	Janssen Pharmaceutica N.V.	Derives de la quinoleine et de la quinazoline 6-heterocyclylmethyle inhibiteurs de la farnesyle transferase
ATE434615T1 (de) *	2000-11-21	2009-07-15	Janssen Pharmaceutica Nv	Farnesyltransferase hemmende benzoheterocyclische derivate
DE60118953T2 (de) *	2000-11-28	2007-01-11	Janssen Pharmaceutica N.V.	Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung
BR0116302A (pt) *	2000-12-19	2004-01-13	Pfizer Prod Inc	Formas cristalinas de sais 2,3-dihidroxibutanodioato de 6-[(4-clorofenil)-hidróxi-(3-metil-3h-imidazol-4-il)-meti l]-4-(3-etinil-fenil)-1-metil-1h-quinolin-2-ona e método de produção
DE60119383T2 (de) *	2000-12-27	2007-04-19	Janssen Pharmaceutica N.V.	Farnesyltransferasehemmende 4-heterocyclylchinolin- und chinazolinderivate
US7129356B2 (en)	2000-12-27	2006-10-31	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
WO2002056884A2 (fr) *	2001-01-22	2002-07-25	Schering Corporation	Traitement du paludisme au moyen d'inhibiteurs de la farnesyl proteine transferase (fpt)
DE60230017D1 (de) *	2001-02-15	2009-01-08	Janssen Pharmaceutica Nv	Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
CA2438421C (fr) *	2001-03-12	2010-05-18	Janssen Pharmaceutica N.V.	Procede de preparation de composes imidazole
US20020151563A1 (en) *	2001-03-29	2002-10-17	Pfizer Inc.	Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
WO2003000705A1 (fr) *	2001-06-21	2003-01-03	Ariad Pharmaceuticals, Inc.	Nouveaux quinolines et leurs utilisations
WO2003000266A1 (fr)	2001-06-21	2003-01-03	Ariad Pharmaceuticals, Inc.	Nouvelles quinoleines et leurs utilisations
US6740757B2 (en)	2001-08-29	2004-05-25	Pfizer Inc	Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
US20030134846A1 (en) *	2001-10-09	2003-07-17	Schering Corporation	Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
JP4537710B2 (ja)	2001-12-19	2010-09-08	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ファルネシルトランスフェラーゼ阻害剤としての炭素連結トリアゾールで置換されている１，８−アネル化キノリン誘導体
JP4450628B2 (ja) *	2002-03-22	2010-04-14	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ファルネシルトランスフェラーゼインヒビターとして使用するためのベンジルイミダゾリル置換２−キノリンおよびキナゾリン誘導体
DE60307616T2 (de)	2002-04-15	2007-10-04	Janssen Pharmaceutica N.V.	Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20030125268A1 (en) *	2002-08-28	2003-07-03	Rybak Mary Ellen Margaret	Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
JP4596916B2 (ja) *	2002-09-05	2010-12-15	メディミューン，エルエルシー	Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法
US7563810B2 (en) *	2002-11-06	2009-07-21	Celgene Corporation	Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) *	2002-11-06	2011-10-11	Celgene Corporation	Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
WO2004091510A2 (fr)	2003-04-11	2004-10-28	Medimmune, Inc.	Anticorps il-9 recombinants et leurs utilisations
US20050003422A1 (en)	2003-07-01	2005-01-06	Mitch Reponi	Methods for assessing and treating cancer
KR20060097105A (ko) *	2003-07-22	2006-09-13	얀센 파마슈티카 엔.브이.	Ｃ-ｆｍｓ 키나아제 저해제로서의 퀴놀리논 유도체
CA2536238C (fr)	2003-08-18	2015-04-07	Medimmune, Inc.	Humanisation d'anticorps
US20060228350A1 (en) *	2003-08-18	2006-10-12	Medimmune, Inc.	Framework-shuffling of antibodies
US7825131B2 (en)	2003-09-23	2010-11-02	Merck Sharp & Dohme Corp.	Quinoline potassium channel inhibitors
WO2005089515A2 (fr) *	2004-03-18	2005-09-29	The Brigham And Women's Hospital, Inc.	Procedes de traitement des synucleinopathies
CA2559221A1 (fr) *	2004-03-18	2005-09-29	Brigham And Women's Hospital, Inc.	Procedes pour le traitement de synucleinopathies
US20050272068A1 (en) *	2004-03-18	2005-12-08	The Brigham And Women's Hospital, Inc.	UCH-L1 expression and cancer therapy
EP1744751A4 (fr) *	2004-03-18	2010-03-10	Brigham & Womens Hospital	Traitement des synucleinopathies
US20070293539A1 (en) *	2004-03-18	2007-12-20	Lansbury Peter T	Methods for the treatment of synucleinopathies
CA2559282A1 (fr) *	2004-03-18	2005-09-29	Brigham And Women's Hospital, Inc.	Procedes pour le traitement de synucleinopathies
CN100567290C (zh) *	2004-05-03	2009-12-09	詹森药业有限公司	锂化n-甲基咪唑在亚磺基亚胺上的非对映选择性加成
EP1756085B1 (fr)	2004-05-03	2010-06-16	Janssen Pharmaceutica N.V.	Procede de synthese diastereoselectif utilisant la 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline
ATE397600T1 (de)	2004-05-03	2008-06-15	Janssen Pharmaceutica Nv	Diastereoselektives syntheseverfahren zur herstellung vn imidazolverbindungen
JP2008504292A (ja)	2004-06-24	2008-02-14	ノバルティスヴァクシンズアンドダイアグノスティクス，インコーポレイテッド	免疫増強用の化合物
GB0420722D0 (en) *	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
CA2585717A1 (fr)	2004-10-27	2006-05-04	Medimmune Inc.	Modulation d'une specificite d'anticorps par adaptation sur mesure de son affinite a un antigene apparente
EP2362218B1 (fr) *	2004-11-05	2014-08-27	Janssen Pharmaceutica N.V.	Methodes de controle de l'efficacite d'inhibiteurs de farnesyltransferase
US20060194821A1 (en) *	2005-02-18	2006-08-31	The Brigham And Women's Hospital, Inc.	Compounds inhibiting the aggregation of superoxide dismutase-1
EP1869192B1 (fr)	2005-03-18	2016-01-20	MedImmune, LLC	Rearrangement de l'infrastructure d'anticorps
EP1888050B1 (fr)	2005-05-17	2012-03-21	Merck Sharp & Dohme Ltd.	Acide cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl) cyclohexanepropanoique pour le traitement du cancer
US20060281769A1 (en) *	2005-06-10	2006-12-14	Baumann Christian A	Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20060281755A1 (en) *	2005-06-10	2006-12-14	Baumann Christian A	Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20070004660A1 (en) *	2005-06-10	2007-01-04	Baumann Christian A	Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
US20060281788A1 (en) *	2005-06-10	2006-12-14	Baumann Christian A	Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
AU2006261920A1 (en)	2005-06-23	2007-01-04	Medimmune, Llc	Antibody formulations having optimized aggregation and fragmentation profiles
TW200804345A (en)	2005-08-30	2008-01-16	Novartis Ag	Substituted benzimidazoles and methods of preparation
ES2347283T3 (es) *	2005-10-14	2010-10-27	Janssen Pharmaceutica N.V.	Formulaciones de tipifarnib para la aplicacion intravenosa.
EP1968591A4 (fr)	2005-12-23	2010-02-17	Link Medicine Corp	Traitement de formes de synucleinopathie
JO2660B1 (en)	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
TWI417095B (zh)	2006-03-15	2013-12-01	Janssen Pharmaceuticals Inc	１，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200808739A (en)	2006-04-06	2008-02-16	Novartis Vaccines & Diagnostic	Quinazolines for PDK1 inhibition
MX2008013427A (es)	2006-04-19	2008-11-04	Novartis Ag	Compuestos de benzoxazole y benzotiazole sustituidos-6-0 y metodos para inhibir la señalizacion csf-1r.
KR101367645B1 (ko)	2006-04-20	2014-02-27	얀센 파마슈티카 엔.브이.	Ｃ-ｆｍｓ 키나제의 저해제로서의 복소환식 화합물
ES2564781T3 (es)	2006-04-20	2016-03-29	Janssen Pharmaceutica, N.V.	Inhibidores de la c-fms quinasa
US8697716B2 (en)	2006-04-20	2014-04-15	Janssen Pharmaceutica Nv	Method of inhibiting C-KIT kinase
JP5209625B2 (ja)	2006-08-28	2013-06-12	協和発酵キリン株式会社	アンタゴニストのヒトｌｉｇｈｔ特異的ヒトモノクローナル抗体
EP2083831B1 (fr)	2006-09-22	2013-12-25	Merck Sharp & Dohme Corp.	Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AR064777A1 (es)	2007-01-10	2009-04-22	Inst Di Reserche D Biolog Mole	Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
CA2679659C (fr)	2007-03-01	2016-01-19	Novartis Ag	Inhibiteurs de pim kinase et procedes de leur utilisation
TW200900065A (en)	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
BRPI0809674A2 (pt)	2007-03-30	2014-10-07	Medimmune Llc	Formulação aquosa estéril, estável, forma de dosagem unitária farmacêutica, recipiente selado, kit, método para prevenir, controlar, tratar ou melhorar uma doença ou distúrbio inflamatório, composição, processo para a preparação de uma composição, e, método para estabilizar um anticorpo 13h5
JO2959B1 (en)	2007-05-14	2016-03-15	جانسين فارماسوتيكا ان. في	Mono-hydrochloric salts for histone dacetylase inhibitor
MX2009012679A (es)	2007-05-21	2009-12-11	Novartis Ag	Inhibidores de csf-1r, composiciones y metodos de uso.
EP2160386B1 (fr) *	2007-05-23	2012-07-11	Allergan, Inc.	Composés thérapeutiques de ((phényl)imidazolyl)méthylquinoléinyle
AU2008269154B2 (en)	2007-06-27	2014-06-12	Merck Sharp & Dohme Llc	4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009033702A1 (fr)	2007-09-14	2009-03-19	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	4-(aryl-x-phényl)-1h-pyridine-2-ones 1,3-disubstituées
PL2203439T3 (pl)	2007-09-14	2011-06-30	Addex Pharmaceuticals Sa	1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony
JO3240B1 (ar)	2007-10-17	2018-03-08	Janssen Pharmaceutica Nv	c-fms مثبطات كيناز
RU2010121967A (ru)	2007-10-31	2011-12-10	Медиммун, Ллк (Us)	Белковые каркасные структуры
JP2011517313A (ja)	2007-12-11	2011-06-02	ビアメトファーマシューティカルズ，インク．	金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
CA2710122A1 (fr)	2007-12-20	2009-07-02	Novartis Ag	Derives de thiazole utilises comme inhibiteur de la pi 3 kinase
WO2009151683A2 (fr) *	2008-03-12	2009-12-17	Link Medicine Corporation	Inhibiteurs de quinolinone farnésyl transférase pour le traitement de synucléinopathies et d'autres indications
US7932036B1 (en)	2008-03-12	2011-04-26	Veridex, Llc	Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
ES2439291T3 (es)	2008-09-02	2014-01-22	Janssen Pharmaceuticals, Inc.	Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
CA2743709A1 (fr) *	2008-11-13	2010-05-20	Link Medicine Corporation	Traitement de proteinopathies utilisant un inhibiteur de farnesyle transferase
US20100331363A1 (en) *	2008-11-13	2010-12-30	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
AU2009313927A1 (en) *	2008-11-13	2010-05-20	Astrazeneca Ab	Azaquinolinone derivatives and uses thereof
US20110060005A1 (en) *	2008-11-13	2011-03-10	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
ES2401691T3 (es)	2008-11-28	2013-04-23	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato
US8691825B2 (en)	2009-04-01	2014-04-08	Merck Sharp & Dohme Corp.	Inhibitors of AKT activity
AU2010246607B2 (en)	2009-05-12	2012-09-27	Addex Pharma S.A.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5634506B2 (ja)	2009-05-12	2014-12-03	ジャンセンファーマシューティカルズ，インコーポレイテッド	１，２，３−トリアゾロ［４，３−ａ］ピリジン誘導体ならびに神経障害および精神障害の治療または予防のためのその使用
US8765747B2 (en)	2009-06-12	2014-07-01	Dana-Farber Cancer Institute, Inc.	Fused 2-aminothiazole compounds
US8293753B2 (en)	2009-07-02	2012-10-23	Novartis Ag	Substituted 2-carboxamide cycloamino ureas
AU2010307198B9 (en)	2009-10-14	2014-02-13	Merck Sharp & Dohme Corp.	Substituted piperidines that increase p53 activity and the uses thereof
EP2519517B1 (fr)	2009-12-29	2015-03-25	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de kinase raf de type ii
BR112012023021A2 (pt)	2010-03-16	2016-05-31	Dana Farber Cancer Inst Inc	compostos de indazol e seus usos
EP2584903B1 (fr)	2010-06-24	2018-10-24	Merck Sharp & Dohme Corp.	Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
EP2598874B1 (fr)	2010-07-28	2018-10-24	Janssen Diagnostics, LLC	Procédés de détermination de réponse de la leucémie myéloïde aiguë à traitement par inhibiteurs de la farnésyltransférase
AR082418A1 (es)	2010-08-02	2012-12-05	Novartis Ag	Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
JP6043285B2 (ja)	2010-08-02	2016-12-14	サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害
LT2606134T (lt)	2010-08-17	2019-07-25	Sirna Therapeutics, Inc.	Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina)
EP2608669B1 (fr)	2010-08-23	2016-06-22	Merck Sharp & Dohme Corp.	Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
US8946216B2 (en)	2010-09-01	2015-02-03	Merck Sharp & Dohme Corp.	Indazole derivatives useful as ERK inhibitors
EP2615916B1 (fr)	2010-09-16	2017-01-04	Merck Sharp & Dohme Corp.	Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
WO2012058210A1 (fr)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA)
JP5852666B2 (ja)	2010-11-08	2016-02-03	ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド	１，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
JP5852665B2 (ja)	2010-11-08	2016-02-03	ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド	１，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES2552455T3 (es)	2010-11-08	2015-11-30	Janssen Pharmaceuticals, Inc.	Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
EP2654748B1 (fr)	2010-12-21	2016-07-27	Merck Sharp & Dohme Corp.	Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
AR085091A1 (es)	2011-01-26	2013-09-11	Kolltan Pharmaceuticals Inc	Anticuerpos anti-kit y sus usos
SG192193A1 (en)	2011-01-31	2013-09-30	Novartis Ag	Novel heterocyclic derivatives
EP2699568A1 (fr)	2011-04-21	2014-02-26	Piramal Enterprises Limited	Forme cristalline d'un sel d'un dérivé de morpholinosulfonylindole et son procédé de préparation
EP2770987B1 (fr)	2011-10-27	2018-04-04	Merck Sharp & Dohme Corp.	Nouveaux composés qui sont des inhibiteurs d'erk
AP2014007601A0 (en)	2011-10-28	2014-04-30	Novartis Ag	Novel purine derivatives and their use in the treatment of disease
US9382239B2 (en)	2011-11-17	2016-07-05	Dana-Farber Cancer Institute, Inc.	Inhibitors of c-Jun-N-terminal kinase (JNK)
EP3453762B1 (fr)	2012-05-02	2021-04-21	Sirna Therapeutics, Inc.	Compositions d'acide nucléique interférent court (sina)
MX360892B (es)	2012-05-16	2018-11-20	Novartis Ag	Régimen de dosificación para un inhibidor de cinasa pi-3.
EP3381943B1 (fr)	2012-07-25	2022-03-16	Celldex Therapeutics, Inc.	Anticorps anti-kit et leurs utilisations
ES2607807T3 (es)	2012-08-07	2017-04-04	Janssen Pharmaceutica Nv	Procedimiento para la preparación de los inibidores de las quinasas c-fms
AU2013299922B2 (en)	2012-08-07	2018-06-21	Janssen Pharmaceutica Nv	Process for the preparation of heterocyclic ester derivatives
EP2900241B1 (fr)	2012-09-28	2018-08-08	Merck Sharp & Dohme Corp.	Nouveaux composés inhibiteurs de erk
WO2014059028A1 (fr)	2012-10-09	2014-04-17	Igenica, Inc.	Anticorps anti-c16orf54 et leurs méthodes d'utilisation
RS56283B1 (sr)	2012-10-16	2017-12-29	Janssen Pharmaceutica Nv	Metilen vezani hinolinil modulatori ror-gama-t
US9303015B2 (en)	2012-10-16	2016-04-05	Janssen Pharmaceutica Nv	Heteroaryl linked quinolinyl modulators of RORγt
WO2014062667A1 (fr)	2012-10-16	2014-04-24	Janssen Pharmaceutica Nv	Modulateurs de ror-gamma-t de type quinolinyle à liaison phényle
WO2014063068A1 (fr)	2012-10-18	2014-04-24	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de cycline-dépendante kinase 7 (cdk7)
WO2014063054A1 (fr)	2012-10-19	2014-04-24	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de kinase moelle osseuse sur chromosome x (bmx) et leurs utilisations
USRE48175E1 (en)	2012-10-19	2020-08-25	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged small molecules as inducers of protein degradation
AU2013352568B2 (en)	2012-11-28	2019-09-19	Merck Sharp & Dohme Llc	Compositions and methods for treating cancer
ES2707305T3 (es)	2012-12-20	2019-04-03	Merck Sharp & Dohme	Imidazopiridinas sustituidas como inhibidores de HDM2
US9540377B2 (en)	2013-01-30	2017-01-10	Merck Sharp & Dohme Corp.	2,6,7,8 substituted purines as HDM2 inhibitors
JO3368B1 (ar)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
WO2014197849A2 (fr)	2013-06-06	2014-12-11	Igenica Biotherapeutics, Inc.	Anticorps anti-c10orf54 et leurs utilisations
HRP20211129T1 (hr)	2013-08-26	2021-10-15	Biontech Research And Development, Inc.	Nukleinske kiseline koje kodiraju humana antitijela na sialyl-lewis a
EP3041938A1 (fr)	2013-09-03	2016-07-13	Moderna Therapeutics, Inc.	Polynucléotides circulaires
JO3367B1 (ar)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
US10555941B2 (en)	2013-10-15	2020-02-11	Janssen Pharmaceutica Nv	Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en)	2013-10-15	2015-12-29	Janssen Pharmaceutica Nv	Secondary alcohol quinolinyl modulators of RORγt
US9403816B2 (en)	2013-10-15	2016-08-02	Janssen Pharmaceutica Nv	Phenyl linked quinolinyl modulators of RORγt
BR112016008258A2 (pt)	2013-10-15	2017-10-10	Janssen Pharmaceutica Nv	moduladores de ror?t de quinolinila
US9328095B2 (en)	2013-10-15	2016-05-03	Janssen Pharmaceutica Nv	Heteroaryl linked quinolinyl modulators of RORgammat
AU2014334619A1 (en)	2013-10-15	2016-04-21	Janssen Pharmaceutica Nv	Alkyl linked quinolinyl modulators of RORyt
US9284308B2 (en)	2013-10-15	2016-03-15	Janssen Pharmaceutica Nv	Methylene linked quinolinyl modulators of RORγt
CN105849099B (zh)	2013-10-18	2020-01-17	达纳-法伯癌症研究所股份有限公司	周期蛋白依赖性激酶7(cdk7)的多环抑制剂
CA2927917C (fr)	2013-10-18	2022-08-09	Syros Pharmaceuticals, Inc.	Composes heteroaromatiques utiles pour le traitement des maladies proliferatives
AU2014358773A1 (en)	2013-12-06	2016-06-02	Novartis Ag	Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
KR20220038826A (ko)	2014-01-21	2022-03-29	얀센 파마슈티카 엔.브이.	대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
KR20200036063A (ko)	2014-01-21	2020-04-06	얀센 파마슈티카 엔.브이.	대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
WO2015164604A1 (fr)	2014-04-23	2015-10-29	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de janus kinase marqués de manière hydrophobe et utilisations associées
US10017477B2 (en)	2014-04-23	2018-07-10	Dana-Farber Cancer Institute, Inc.	Janus kinase inhibitors and uses thereof
US11311519B2 (en)	2014-05-01	2022-04-26	Eiger Biopharmaceuticals, Inc.	Treatment of hepatitis delta virus infection
US10076512B2 (en)	2014-05-01	2018-09-18	Eiger Biopharmaceuticals, Inc.	Treatment of hepatitis delta virus infection
US9856324B2 (en)	2014-06-04	2018-01-02	MabVax Therapeutics, Inc.	Human monoclonal antibodies to ganglioside GD2
JO3589B1 (ar)	2014-08-06	2020-07-05	Novartis Ag	مثبطات كيناز البروتين c وطرق استخداماتها
DK3229838T3 (da)	2014-12-11	2020-10-19	Pf Medicament	Anti-C10orf54-antistoffer og anvendelser deraf
AU2015371251B2 (en)	2014-12-23	2020-06-11	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
FI3265123T3 (fi)	2015-03-03	2023-01-31		Vasta-aineita, käyttöjä & menetelmiä
EP3273966B1 (fr)	2015-03-27	2023-05-03	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de kinases cycline-dépendantes
DK3285768T3 (da)	2015-04-21	2021-01-25	Eiger Biopharmaceuticals Inc	Farmaceutiske sammensætninger omfattende lonafarnib og ritonavir
US10702527B2 (en)	2015-06-12	2020-07-07	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
HRP20211976T1 (hr)	2015-08-17	2022-03-18	Kura Oncology, Inc.	Postupci liječenja bolesnika od raka inhibitorima farnezil transferaze
US9815790B2 (en)	2015-08-27	2017-11-14	Janssen Pharmaceutica Nv	Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists
EP3347018B1 (fr)	2015-09-09	2021-09-01	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de kinases cycline-dépendantes
HK1252411A1 (zh)	2015-11-02	2019-05-24	Novartis Ag	磷脂酰肌醇3-激酶抑制剂的给药方案
EP3383908A1 (fr)	2015-12-02	2018-10-10	Stsciences, Inc.	Anticorps spécifiques au btla glycosylé (atténuateur de lymphocytes b et t)
WO2017096051A1 (fr)	2015-12-02	2017-06-08	Stcube & Co., Inc.	Anticorps et molécules se liant de manière immunospécifique à btn1a1 et leurs utilisations thérapeutiques
JOP20190055A1 (ar)	2016-09-26	2019-03-24	Merck Sharp & Dohme	أجسام مضادة ضد cd27
WO2018060833A1 (fr)	2016-09-27	2018-04-05	Novartis Ag	Schéma posologique pour l'alpelisib, un inhibiteur de la phosphatidylinositol 3-kinase spécifique de l'isoforme alpha
WO2018071283A1 (fr)	2016-10-12	2018-04-19	Merck Sharp & Dohme Corp.	Inhibiteurs de kdm5
EP3534947A1 (fr)	2016-11-03	2019-09-11	Kymab Limited	Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
EP3838275A1 (fr)	2016-11-03	2021-06-23	Kura Oncology, Inc.	Inhibiteurs de farnésyltransférase pour utilisation dans le traitement de cancer
CN110234639A (zh)	2016-12-08	2019-09-13	杭州领业医药科技有限公司	替吡法尼的晶型及其制备方法及药物组合物
MX2019012233A (es)	2017-04-13	2020-01-14	Aduro Biotech Holdings Europe Bv	Anticuerpos anti-sirpa.
WO2018222685A1 (fr)	2017-05-31	2018-12-06	Stcube & Co., Inc.	Méthodes de traitement du cancer à l'aide d'anticorps et de molécules se liant de manière immunospécifique à btn1a1
CA3065301A1 (fr)	2017-05-31	2018-12-06	Stcube & Co., Inc.	Anticorps et molecules se liant de maniere immunospecifique a btn1a1 et leurs utilisations therapeutiques
WO2018226671A1 (fr)	2017-06-06	2018-12-13	Stcube & Co., Inc.	Procédés de traitement du cancer à l'aide d'anticorps et de molécules se liant à btn1a1 ou des ligands de btn1a1
EP3694889A1 (fr)	2017-10-13	2020-08-19	Boehringer Ingelheim International GmbH	Anticorps humains dirigés contre l'antigène thomsen-nouveau (tn)
US11098059B2 (en)	2017-11-08	2021-08-24	Merck Sharp & Dohme Corp.	PRMT5 inhibitors
WO2019094311A1 (fr)	2017-11-08	2019-05-16	Merck Sharp & Dohme Corp.	Inhibiteurs de prmt5
WO2019113269A1 (fr)	2017-12-08	2019-06-13	Kura Oncology, Inc.	Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
WO2019148412A1 (fr)	2018-02-01	2019-08-08	Merck Sharp & Dohme Corp.	Anticorps bispécifiques anti-pd-1/lag3
AU2019270163A1 (en)	2018-05-18	2020-12-03	Kura Oncology, Inc.	Synthesis of tipifarnib
WO2020005807A1 (fr)	2018-06-25	2020-01-02	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de kinase de la famille taire et utilisations correspondantes
IL280199B2 (en)	2018-07-20	2025-08-01	Pf Medicament	Receptor for vista
US11993602B2 (en)	2018-08-07	2024-05-28	Merck Sharp & Dohme Llc	PRMT5 inhibitors
US12552826B2 (en)	2018-08-07	2026-02-17	Merck Sharp & Dohme Llc	PRMT5 inhibitors
WO2020033284A1 (fr)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Inhibiteurs de prmt5
US12173026B2 (en)	2018-08-07	2024-12-24	Merck Sharp & Dohme Llc	PRMT5 inhibitors
JP7660063B2 (ja)	2018-12-28	2025-04-10	ダナ－ファーバーキャンサーインスティテュート，インコーポレイテッド	サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
TW202108170A (zh)	2019-03-15	2021-03-01	美商庫拉腫瘤技術股份有限公司	以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
WO2021126732A1 (fr)	2019-12-17	2021-06-24	Merck Sharp & Dohme Corp.	Inhibiteurs de prmt5
US12441730B2 (en)	2019-12-17	2025-10-14	Merck Sharp & Dohme Llc	PRMT5 inhibitors
CA3234276A1 (fr) *	2021-11-30	2023-06-08	Kura Oncology, Inc.	Composes macrocycliques ayant une activite inhibitrice de la farnesyltransferase
WO2023141082A1 (fr) *	2022-01-20	2023-07-27	Teva Czech Industries S.R.O.	Formes à l'état solide de tipifarnib et leur procédé de préparation
CN120917311A (zh)	2023-03-02	2025-11-07	卡西蒙生物技术有限责任公司	用于诊断癌症和/或急性炎性疾病的手段和方法
MX2025014317A (es) *	2023-05-31	2026-02-03	Kura Oncology Inc	Formas solidas de un inhibidor macrociclico de farnesiltransferasa y formulaciones de estos y metodos de preparacion y uso del compuesto macrociclico y sus formas solidas
CN117229206B (zh) *	2023-09-18	2025-01-03	延安大学	一种碱催化合成多取代2-喹啉酮类化合物的制备方法
WO2026027944A1 (fr)	2024-07-30	2026-02-05	Sairopa B.V.	Formulations d'anticorps anti-sirp alpha et leurs utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2101115A (en) *	1980-10-23	1983-01-12	Pfizer Ltd	Thromboxane synthetase inhibitors
CA2002864C (fr) *	1988-11-29	1999-11-16	Eddy J. E. Freyne	Derives de quinoline, quinazoline ou quinoxaline (1h-azol-1-ylmethyl) substitues
ES2175137T3 (es) *	1995-12-08	2002-11-16	Janssen Pharmaceutica Nv	Derivados de (imidazol-5-il)metil-2-quinolinona como inhibidores de laproteina farnesil-transferasa.

1996
- 1996-10-16 ES ES96934727T patent/ES2175137T3/es not_active Expired - Lifetime
- 1996-10-16 SI SI9630477T patent/SI0865440T1/xx unknown
- 1996-10-16 CN CN96198750A patent/CN1101392C/zh not_active Expired - Lifetime
- 1996-10-16 TR TR1998/00825T patent/TR199800825T2/xx unknown
- 1996-10-16 AT AT01202750T patent/ATE321757T1/de active
- 1996-10-16 NZ NZ320244A patent/NZ320244A/xx not_active IP Right Cessation
- 1996-10-16 DK DK01202750T patent/DK1162201T3/da active
- 1996-10-16 DK DK96934727T patent/DK0865440T3/da active
- 1996-10-16 WO PCT/EP1996/004515 patent/WO1997021701A1/fr not_active Ceased
- 1996-10-16 ES ES01202750T patent/ES2260156T3/es not_active Expired - Lifetime
- 1996-10-16 SI SI9630736T patent/SI1162201T1/sl unknown
- 1996-10-16 AP APAP/P/1998/001257A patent/AP1108A/en active
- 1996-10-16 PL PL96325962A patent/PL184171B1/pl unknown
- 1996-10-16 CZ CZ19981573A patent/CZ293296B6/cs not_active IP Right Cessation
- 1996-10-16 UA UA98052686A patent/UA57717C2/uk unknown
- 1996-10-16 JP JP52163897A patent/JP3257559B2/ja not_active Expired - Lifetime
- 1996-10-16 US US09/084,717 patent/US6037350A/en not_active Expired - Lifetime
- 1996-10-16 EP EP01202750A patent/EP1162201B1/fr not_active Expired - Lifetime
- 1996-10-16 AT AT96934727T patent/ATE215541T1/de active
- 1996-10-16 BR BR9610745A patent/BR9610745A/pt not_active IP Right Cessation
- 1996-10-16 SK SK704-98A patent/SK283335B6/sk not_active IP Right Cessation
- 1996-10-16 PT PT01202750T patent/PT1162201E/pt unknown
- 1996-10-16 IL IL12356896A patent/IL123568A/en not_active IP Right Cessation
- 1996-10-16 DE DE69620445T patent/DE69620445T2/de not_active Expired - Lifetime
- 1996-10-16 HU HU9900185A patent/HU221227B1/hu unknown
- 1996-10-16 EP EP96934727A patent/EP0865440B1/fr not_active Expired - Lifetime
- 1996-10-16 PT PT96934727T patent/PT865440E/pt unknown
- 1996-10-16 DE DE69635966T patent/DE69635966T2/de not_active Expired - Lifetime
- 1996-10-16 AU AU72948/96A patent/AU711142B2/en not_active Expired
- 1996-10-16 EE EE9800146A patent/EE03484B1/xx unknown
- 1996-10-16 EA EA199800443A patent/EA000710B1/ru not_active IP Right Cessation
- 1996-10-16 CA CA002231105A patent/CA2231105C/fr not_active Expired - Lifetime
- 1996-10-16 KR KR1019980702363A patent/KR100272676B1/ko not_active Expired - Lifetime
- 1996-11-30 TW TW085114832A patent/TW494101B/zh not_active IP Right Cessation
- 1996-12-05 ZA ZA9610254A patent/ZA9610254B/xx unknown
- 1996-12-05 HR HR960576A patent/HRP960576B1/xx not_active IP Right Cessation
- 1996-12-06 MY MYPI96005129A patent/MY114444A/en unknown
- 1996-12-06 AR ARP960105548A patent/AR004992A1/es active IP Right Grant
1998
- 1998-03-04 NO NO19980927A patent/NO314036B1/no not_active IP Right Cessation
- 1998-03-16 MX MX9802068A patent/MX9802068A/es unknown
- 1998-05-18 BG BG102458A patent/BG62615B1/xx unknown
1999
- 1999-07-29 US US09/363,353 patent/US6169096B1/en not_active Expired - Lifetime
2000
- 2000-10-12 US US09/689,211 patent/US6420387B1/en not_active Expired - Lifetime
2002
- 2002-04-17 HK HK02102891.4A patent/HK1042482B/en not_active IP Right Cessation
- 2002-07-30 CY CY0200047A patent/CY2289B1/xx unknown

Also Published As

Publication number	Publication date
TR199800825T2 (xx)	1998-08-21
DE69635966D1 (de)	2006-05-18
EP0865440B1 (fr)	2002-04-03
IL123568A (en)	2001-08-08
BG62615B1 (en)	2000-03-31
CZ293296B6 (cs)	2004-03-17
PT865440E (pt)	2002-09-30
MY114444A (en)	2002-10-31
NO980927D0 (no)	1998-03-04
US6169096B1 (en)	2001-01-02
CN1203598A (zh)	1998-12-30
JPH10511405A (ja)	1998-11-04
KR19990063891A (ko)	1999-07-26
ATE215541T1 (de)	2002-04-15
HRP960576A2 (en)	1998-02-28
JP3257559B2 (ja)	2002-02-18
SI0865440T1 (en)	2002-08-31
CA2231105A1 (fr)	1997-06-19
CN1101392C (zh)	2003-02-12
HUP9900185A2 (hu)	1999-04-28
EA000710B1 (ru)	2000-02-28
ES2260156T3 (es)	2006-11-01
CZ157398A3 (cs)	1998-10-14
HU221227B1 (en)	2002-08-28
CY2289B1 (en)	2003-07-04
EP1162201A2 (fr)	2001-12-12
BR9610745A (pt)	1999-07-13
PT1162201E (pt)	2006-08-31
AU7294896A (en)	1997-07-03
AU711142B2 (en)	1999-10-07
DK0865440T3 (da)	2002-07-22
US6420387B1 (en)	2002-07-16
EP1162201A3 (fr)	2003-11-26
EE9800146A (et)	1998-10-15
TW494101B (en)	2002-07-11
WO1997021701A1 (fr)	1997-06-19
UA57717C2 (uk)	2003-07-15
US6037350A (en)	2000-03-14
ZA9610254B (en)	1998-06-05
DE69635966T2 (de)	2006-11-30
DE69620445D1 (de)	2002-05-08
EP0865440A1 (fr)	1998-09-23
IL123568A0 (en)	1998-10-30
SK283335B6 (sk)	2003-06-03
KR100272676B1 (ko)	2000-11-15
HK1042482A1 (en)	2002-08-16
EP1162201B1 (fr)	2006-03-29
NZ320244A (en)	1999-06-29
ES2175137T3 (es)	2002-11-16
DE69620445T2 (de)	2002-12-12
HUP9900185A3 (en)	1999-11-29
NO314036B1 (no)	2003-01-20
HK1012188A1 (en)	1999-07-30
SI1162201T1 (sl)	2006-08-31
PL184171B1 (pl)	2002-09-30
DK1162201T3 (da)	2006-07-17
AR004992A1 (es)	1999-04-07
AP9801257A0 (en)	1998-06-30
BG102458A (en)	1999-06-30
CA2231105C (fr)	2005-09-13
EA199800443A1 (ru)	1998-10-29
SK70498A3 (en)	1998-10-07
NO980927L (no)	1998-06-08
PL325962A1 (en)	1998-08-17
ATE321757T1 (de)	2006-04-15
AP1108A (en)	2002-10-02
MX9802068A (es)	1998-08-30
HRP960576B1 (en)	2002-04-30
EP1162201A9 (fr)	2002-04-03
HK1042482B (en)	2006-06-09

Legal Events

Date	Code	Title	Description
2003-02-17	KB4A	Valid patent at the end of a year	Effective date: 20021231
2004-02-16	KB4A	Valid patent at the end of a year	Effective date: 20031231
2005-02-15	KB4A	Valid patent at the end of a year	Effective date: 20041231
2006-02-15	KB4A	Valid patent at the end of a year	Effective date: 20051231
2007-02-15	KB4A	Valid patent at the end of a year	Effective date: 20061231
2008-02-15	KB4A	Valid patent at the end of a year	Effective date: 20071231
2009-02-16	KB4A	Valid patent at the end of a year	Effective date: 20081231
2010-02-15	KB4A	Valid patent at the end of a year	Effective date: 20091231
2011-02-15	KB4A	Valid patent at the end of a year	Effective date: 20101231

Publication	Publication Date	Title
EE03484B1 (et)	2001-08-15	Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine
IS4568A (is)	1997-09-24	Farnesýl-prótein transferasa latar
EP0841919A4 (fr)	1999-02-24	Inhibiteurs de la farnesyle-proteine transferase
NO985405D0 (no)	1998-11-20	Inhibitorer av proteinfarnesyltransferase
EP1011669A4 (fr)	2001-09-12	Inhibiteurs de la farnesyl-proteine transferase
FI952010L (fi)	1995-04-27	Farnesyyliproteiinitransferaasin estäjät
FI952011L (fi)	1995-04-27	Farnesyyliproteiinitransferaasin estäjät
EE9800262A (et)	1999-02-15	Farnesüül-proteiini transferaasi inhibiitorid
FI961621L (fi)	1996-04-12	Proteiini:farnesyylitranseraasin substituoidut tetra- ja pentapeptidi-inhibiittorit
FI951554A0 (fi)	1995-03-31	Imidatsolipitoisia farnesyyliproteiinitransferaasi-inhibiittoreita
FI924747A7 (fi)	1993-04-22	PEG-imidaatteja ja niiden proteiinijohdannaisia
EP0777475A4 (fr)	1997-12-03	Inhibiteurs de la farnesyle-proteine transferase
FI941519A7 (fi)	1994-10-03	Farnesyyliproteiinitransferaasin heterosyklisiä inhibiittoreita
EP0784473A4 (fr)	1997-12-17	Inhibiteurs de la farnesyl-transferase proteique
EP0891360A4 (fr)	2002-05-15	Inhibiteurs de la farnesyl-proteine transferase
EP0783318A4 (fr)	1999-10-20	Inhibiteurs de farnesyle-proteine transferase
EP0783305A4 (fr)	1998-04-01	Inhibiteurs de farnesyle-proteine transferase
EP0812203A4 (fr)	1999-04-14	Inhibiteurs de geranylgeranyle-proteine transferase
EP0891352A4 (fr)	2001-08-16	Inhibiteurs de la farnesyl-proteine transferase
EP1035850A4 (fr)	2001-09-12	Inhibiteurs de la transferase de la farnesyl-proteine
EP1035852A4 (fr)	2001-09-12	Inhibiteurs de la farnesyl-proteine transferase
EP0891353A4 (fr)	2001-08-08	Inhibiteurs de farnesyle-proteine transferase
EP0787123A4 (fr)	1999-10-13	Inhibiteurs de farnesyle-proteine transferase
EP1035849A4 (fr)	2001-09-12	Inhibiteurs de la transferase de la farnesyl-proteine
EP0959883A4 (fr)	2001-05-09	Inhibiteurs de la farnesyle-proteine transferase